Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Supportive Care in Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00520-009-0797-xPMID 20101417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre

  2008cited by this paper
• Chemotherapy-induced nausea and vomiting.

  2008cited by this paper
• Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.

  2007cited by this paper
• Costs of uncontrolled chemotherapy‐induced nausea and vomiting among working‐age cancer patients receiving highly or moderately emetogenic chemotherapy

  2007influential reference
• Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings

  2007cited by this paper
• The impact of chemotherapy-induced nausea and vomiting on health-related quality of life

  2007cited by this paper
• In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.

  2006cited by this paper
• Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

  2006cited by this paper
• The cost of chemotherapy-induced nausea and vomiting in Italy

  2006cited by this paper
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

  2006cited by this paper
• American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

  2006cited by this paper
• Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’ estimation vs. patients’ reported outcomes

  2005cited by this paper
• Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada.

  2005cited by this paper
• Use of complementary and alternative medicine in cancer patients: a European survey.

  2005cited by this paper
• The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.

  2004influential reference
• Chemotherapy-induced nausea and vomiting in routine practice: a European perspective

  2004cited by this paper
• Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics

  2004cited by this paper
• Derivation of Malignancy Status from ICD-9 Codes

  2003cited by this paper
• Why do we need another antiemetic? Just ask.

  2003cited by this paper
• Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.

  1999cited by this paper
• Initial control of chemotherapy-induced nausea and vomiting in patient quality of life.

  1998cited by this paper
• INITIAL CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENT QUALITY OF LIFE

  1998cited by this paper
• Chemotherapy induced nausea and vomiting.

  1994cited by this paper
• Simplified calculation of body-surface area.

  1987influential reference
• Simplified Calculation of Body-Surface Area

  1987cited by this paper

• Practical Considerations for the Use of Antiemetics in Pregnant Patients With Breast Cancer.

  2026cites this paper
• Real-World Determinants of Olanzapine Prescribing for Antiemetic Prophylaxis in Adults Receiving Highly-Emetogenic Chemotherapy.

  2025cites this paper
• Feasible HPLC method for simultaneous determination of triple therapy prescribed for cancer patients with application to human plasma: Method’s greenness, whiteness, and blueness appraisal

  2025cites this paper
• Approach to Meal-Related Nausea and Vomiting.

  2025cites this paper
• Impact of oncology pharmacy services on the management of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.

  2024cites this paper
• Efficacy and Safety of Ginger on Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

  2024cites this paper
• Challenges in chemotherapy induced nausea and vomiting (CINV) management: A systematic review

  2024cites this paper
• Improving the prediction of chemotherapy dose-limiting toxicity in colon cancer patients using an AI-CT-based 3D body composition of the entire L1–L5 lumbar spine

  2024cites this paper
• Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer

  2023cites this paper
• Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy

  2023cites this paper
• Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.

  2023cites this paper
• A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

  2023cites this paper
• Cost-Effectiveness Analysis of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine for Patients with HER2+ Metastatic Breast Cancer in the United States.

  2023cites this paper
• Vomiting after intrathecal chemotherapy under anesthesia in pediatric patients with hematologic cancers: A cohort study

  2023cites this paper
• Fosaprepitant: current options to prevent chemotherapy-induced nausea and vomiting: A review

  2023cites this paper
• Acupuncture for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients: A systematic review and meta‐analysis

  2023cites this paper
• Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective

  2022cites this paper
• Prevention Strategy of Chemotherapy-Induced Nausea and Vomiting (CINV) with Olanzapine: Alternative Option

  2022cites this paper
• Understanding the Extent of Polypharmacy and its Association With Health Service Utilization Among Persons With Cancer and Multimorbidity: A Population-Based Retrospective Cohort Study in Ontario, Canada

  2022cites this paper
• A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice

  2022cites this paper
• Impact of applying virtual reality computer games on complications among children undergoing chemotherapy

  2022cites this paper
• Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting

  2021cites this paper
• Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.

  2021cites this paper
• Title:Chemotherapy-induced nausea and vomiting breast cancer patients from a Chinese multicenter prospective longitudinal observational study

  2021cites this paper
• Pediatric related risk factors in acute and delayed chemotherapyinduced nausea and vomiting: multivariate analysis

  2021cites this paper
• Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.

  2021cites this paper
• Effect of Video Games on the Adverse Corollaries of Chemotherapy at Pediatric Oncology Patients

  2021cites this paper
• Metagenomics and chemotherapy‐induced nausea: A roadmap for future research

  2021cites this paper
• Unplanned emergency department visits and hospital admissions of older adults under treatment for cancer in the ambulatory/community setting

  2021cites this paper
• Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients: A Multicenter Prospective Observational Study

  2021cites this paper
• Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain

  2021cites this paper
• Reconsidering dexamethasone for anti-emesis when combining chemotherapy and immunotherapy.

  2021cites this paper
• Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.

  2020cites this paper
• Ultra-low doses of the transient receptor potential vanilloid 1 agonist, resiniferatoxin, prevents vomiting evoked by diverse emetogens in the least shrew (Cryptotis parva)

  2020cites this paper
• Research priorities on falls in older adults with cancer.

  2020cites this paper
• Initiatives to Improve Control, Resource Use, and Quality of Life Associated with Chemotherapy- Induced Nausea and Vomiting

  2020cites this paper
• Avoidable acute care use associated with nausea and vomiting among patients receiving highly emetogenic chemotherapy or oxaliplatin.

  2020cites this paper
• Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends.

  2020cites this paper
• Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective

  2020cites this paper
• What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.

  2020cites this paper
• Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?

  2020cites this paper
• Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.

  2019cites this paper
• Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis

  2019cites this paper
• Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy‐induced nausea and vomiting in pediatric cancer patients

  2019cites this paper
• Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy

  2019cites this paper
• Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.

  2019cites this paper
• Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting

  2019cites this paper
• Hydration requirements in patients receiving highly emetogenic chemotherapy.

  2019cites this paper
• Recent Advances in Antiemetics

  2019cites this paper
• Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study

  2019cites this paper
• Effect of Story-Telling on Reducing the Intensity of Nausea and Vomiting among Children Undergoing Chemotherapy

  2019cites this paper
• Cost‐effectiveness of aprepitant in Japanese patients treated with cisplatin‐containing highly emetogenic chemotherapy

  2018cites this paper
• Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

  2018cites this paper
• Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.

  2018cites this paper
• Jordanian oncology nurses' knowledge of managing chemotherapy-induced nausea and vomiting.

  2018cites this paper
• Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.

  2018cites this paper
• Emergency department presentations in early stage breast cancer patients receiving adjuvant and neoadjuvant chemotherapy

  2018cites this paper
• Factors Associated with Emergency Department Utilization and Admission in Patients with Colorectal Cancer

  2018cites this paper
• A Cancer Patient Suffering from Chemotherapy-Induced Anorexia and Nausea Treated by Herbal Medicine ( Dokhwaljihwang-tang-gamibang ) Resulted in Improved Quality of Life: A Case Report

  2018cites this paper
• Cost-effectiveness of newer anti-emetics in the prevention of chemotherapy induced nausea and vomiting: a pharmaco-economic study analysis

  2018cites this paper
• Effect of Therapeutic Massage on nausea and vomitingamong Children with Leukemia following Chemotherapy

  2018cites this paper
• Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists

  2018influential citation
• A Cancer Patient Suffering from Chemotherapy-Induced Anorexia and Nausea Treated by Herbal Medicine (Dokhwaljihwang-tang-gamibang) Resulted in Improved Quality of Life: A Case Report

  2018cites this paper
• Strategies to improve CINV outcomes in managed care.

  2018cites this paper
• Merit-based Claim Adjudication for Cancer Treatment Toxicities - Policy Trends that Lower Downstream Costs.

  2018cites this paper
• Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting A systematic literature review Marx,

  2017cites this paper
• Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic

  2017cites this paper
• The Effectiveness of Hologram Bracelets in Reducing Chemotherapy-Induced Nausea and Vomiting Among Adult Patients With Cancer

  2017cites this paper
• New options and controversies in the management of chemotherapy‐induced nausea and vomiting

  2017cites this paper
• Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management

  2017influential citation
• US oncology-wide incidence, duration, costs and deaths from chemoradiation mucositis and antimucositis therapy benefits.

  2017cites this paper
• Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.

  2017cites this paper
• Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV

  2017cites this paper
• Complete prevention and rapid sustained elimination of chemoradiation toxic mucositis, a case series with implications for mucositis pathobiology, cost of care, morbidity and premature cancer deaths

  2017cites this paper
• Is Rolapitant Effective in Reducing the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Emetogenic Chemotherapy?

  2017influential citation
• Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer

  2016cites this paper
• Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries

  2016cites this paper
• Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer

  2016cites this paper
• The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting

  2016cites this paper
• Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis

  2016cites this paper
• Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review.

  2016cites this paper
• Cost-consequence analysis of aprepitant compared to standard therapy (5-HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit

  2015cites this paper
• Cost savings associated with antibiotic-impregnated shunt catheters in the treatment of adult and pediatric hydrocephalus.

  2015cites this paper
• Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System

  2015cites this paper
• Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis

  2015cites this paper
• Standardized ginger (Zingiber officinale) extract as a treatment for chemotherapy-induced nausea and vomiting: efficacy, safety and feasibility.

  2015cites this paper
• Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens.

  2015cites this paper
• Comparative effectiveness of antibiotic-impregnated shunt catheters in the treatment of adult and pediatric hydrocephalus: analysis of 12,589 consecutive cases from 287 US hospital systems.

  2015cites this paper
• Costs and length of stay of drug-related hospital admissions in cancer patients.

  2014cites this paper
• Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.

  2014cites this paper
• Outcomes Associated with 5-HT 3 -RA Therapy Selection in Patients with Chemotherapy- Induced Nausea and Vomiting: A Retrospective

  2014cites this paper
• Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study

  2014cites this paper
• Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.

  2014cites this paper
• Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting

  2014cites this paper
• Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice

  2014cites this paper
• Use of and spending on supportive care medications among Medicare beneficiaries with cancer

  2014cites this paper
• Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.

  2014cites this paper
• Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors

  2013cites this paper
• Perspectives on Improving the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting (CINV) Developing Clinically and Economically Efficient Antiemetic Regimens

  2013cites this paper
• Chapter 71 – What Are the Arguments That Show Outpatient Palliative Care Is Beneficial to Medical Systems?

  2013cites this paper